Journal of Cardiovascular Pharmacology · 1986 · 22 citations · 0 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyPharmacodynamicsPulmonary Function TestingAsthma ManagementAsthma PharmacotherapyBronchodilator TherapyInhalation Dosage FormsInhaled Medication AdministrationAdult Asthma PharmacotherapyBeta-3 Agonist TherapyBeta2-adrenergic Agonist TherapyForced Expiratory Volume AssessmentForced Expiratory Volume DeclinePharmacodynamics Of Inhaled DrugsPropranolol TherapySerial Forced Expiratory Volume Monitoring
The bronchopulmonary effects of celiprolol were studied in 12 male asthmatic patients who showed mean maximum changes of -24% in forced one-second expiratory volume (FEV1) and 130% in airways resistance (Raw) following a single, 80 mg dose of propranolol. Celiprolol 200 and 400 mg and placebo were administered in double-blind, random fashion. Raw and FEV1 were determined by whole body plethysmography 1, 2, and 3 h post dose. For placebo and celiprolol 200 and 400 mg, mean maximum changes in FEV1 were 0.6, 2.8, and 2.4%, and for Raw, 11.3, -0.2, and -10.9%, respectively. Pulmonary effects of the three treatments were indistinguishable but differed significantly from propranolol. Five 0.5 mg doses of terbutaline aerosol, administered at 15-min intervals starting 3 h post drug or placebo, caused less bronchodilation after propranolol than after placebo, or celiprolol 200 or 400 mg; the responses after the latter three were indistinguishable. These results suggest that celiprolol is highly bronchosparing and does not block bronchodilation following the beta 2-agonist terbutaline in propranolol-sensitive asthmatics. In contrast to classical beta-adrenoceptor antagonists, celiprolol may afford a greater margin of safety in asthmatic patients with angina or hypertension.